Pharma Giants Ramp Up U.S. Investments Amid Tariff Threat

Global pharmaceutical companies are increasing U.S. production and investments in response to potential 100% tariffs on branded drugs under the Trump administration. Major drugmakers like Pfizer, AstraZeneca, and others have committed billions to U.S.-based research and manufacturing to mitigate supply chain risks and minimize tariff impacts.

International pharmaceutical companies are significantly boosting their U.S. manufacturing efforts in anticipation of 100% tariffs on branded drugs proposed by the Trump administration. Firms like Pfizer and AstraZeneca have secured multi-year tariff exemptions by agreeing to pricing deals and commitments on the new TrumpRx.gov platform.

These commitments have led to a surge in U.S. investments, with companies like Eli Lilly and Johnson & Johnson pledging billions for U.S. operations to sidestep penalties. Lilly, for example, plans to construct new facilities in several states, including Alabama and Virginia, as part of its strategic expansion.

Amid the looming tariff threat, Roche, Novartis, and Sanofi are also ramping up their U.S. investments, focusing on infrastructure and production capabilities to safeguard against potential financial setbacks and ensure continuous supply chain efficacy.